Table 2.
Characteristics of the studies selected.
| Author ID | Study Design | Intervention | Year of Publication | No. of Subjects | Prior Line of Rx | HER2 Mutation | RAS Mutation | BRAF Mutation |
|---|---|---|---|---|---|---|---|---|
| Tsurutani et al. [29] | Non-randomized phase 1 dose expansion clinical trial | Trastuzumab deruxtecan | March 2020 | 20 | 4 | 5 Kinase domain, 1 Transmembrane domain, and 0 Extracellular domain | 5 KRAS and 2 NRAS | - |
| Fu et al. [34] | Non-randomized phase 2 trial | Trastuzumab + Pyrotinib | March 2023 | 18 | 2 | 5 HER2 | 12 RAS wild-type, 5 KRAS and 1 NRAS | - |
| Bianchi et al. [30] | Single arm, multicenter, phase 2 clinical trial |
Pertuzumab + Trastuzumab emtansine | January 2020 | 31 | 3 | - | - | - |
| Strickler et al. [35] | Open-label phase 2 clinical trial | Trastuzumab + Tucatinib | January 2023 | 84 | 3 | - | - | - |
| Tosi et al. [31] |
Open-label Phase 2 Non-randomized |
Trastuzumab + Lapatinib | January 2020 | 32 | 5 | - | 32 KRAS exon 2 (codons 12 and 13) wild-type | - |
| Siena et al. [32] |
Open-label Phase 2 Non-randomized |
Trastuzuma deruxtecan | June 2023 | 53 | 2 | - | 52 RAS wild-type and 1 NRAS | 53 BRAF wild-type |